The Antifolates

Overview

Journal Hematol Oncol Clin North Am

Specialties Hematology
Oncology

Date 2012 Apr 24

PMID 22520983

Citations 129

Authors

Michele Visentin

Rongbao Zhao

I David Goldman

Affiliations

Soon will be listed here.

Abstract

This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mechanisms of resistance, and transport into and out of cells has led to the development of a new generation of antifolates, a process that continues in the laboratory and in the clinics. New approaches to folate-based cancer chemotherapy are described based on the targeted delivery of drugs to malignant cells.

Citing Articles

Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age.

Liu Y, Chen X, Evan T, Esapa B, Chenoweth A, Cheung A MAbs. 2025; 17(1):2470309.

PMID: 40045156 PMC: 11901361. DOI: 10.1080/19420862.2025.2470309.

DHFR2 RNA directly regulates dihydrofolate reductase and its expression level impacts folate one carbon metabolism.

Drago P, Bookey N, Leung K, Henry M, Meleady P, Greene N FASEB J. 2025; 39(4):e70391.

PMID: 39957677 PMC: 11831416. DOI: 10.1096/fj.202401039RR.

Peptide hydrogel-drug conjugates for tailored disease treatment.

Cauwenbergh T, Ballet S, Martin C Mater Today Bio. 2025; 31:101423.

PMID: 39944533 PMC: 11815290. DOI: 10.1016/j.mtbio.2024.101423.

Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions.

Flickinger K, Wilson K, Rossiter N, Hunger A, Vishwasrao P, Lee T Sci Adv. 2024; 10(40):eadq3591.

PMID: 39365851 PMC: 11451515. DOI: 10.1126/sciadv.adq3591.

Low dose methotrexate impaired T cell transmigration through down-regulating CXCR4 expression in rheumatoid arthritis (RA).

Ding L, Park D, Gao B, Wu L, Li M, Abedelhakim H Arthritis Res Ther. 2024; 26(1):173.

PMID: 39350214 PMC: 11440717. DOI: 10.1186/s13075-024-03403-9.

References

Salazar M, Ratnam M . The folate receptor: what does it promise in tissue-targeted therapeutics?. Cancer Metastasis Rev. 2007; 26(1):141-52. DOI: 10.1007/s10555-007-9048-0. View

Allegra C, Chabner B, Drake J, Lutz R, Rodbard D, Jolivet J . Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem. 1985; 260(17):9720-6. View

Reddy J, Xu L, Parker N, Vetzel M, Leamon C . Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med. 2004; 45(5):857-66. View

Allegra C, Drake J, Jolivet J, Chabner B . Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A. 1985; 82(15):4881-5. PMC: 390461. DOI: 10.1073/pnas.82.15.4881. View

Braus N, Elliott D . Advances in the pathogenesis and treatment of IBD. Clin Immunol. 2009; 132(1):1-9. PMC: 2693446. DOI: 10.1016/j.clim.2009.02.006. View

Chen M, Kallenberg C . ANCA-associated vasculitides--advances in pathogenesis and treatment. Nat Rev Rheumatol. 2010; 6(11):653-64. DOI: 10.1038/nrrheum.2010.158. View

Reddy J, Dorton R, Westrick E, Dawson A, Smith T, Xu L . Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 2007; 67(9):4434-42. DOI: 10.1158/0008-5472.CAN-07-0033. View

Matloub Y, Bostrom B, Hunger S, Stork L, Angiolillo A, Sather H . Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011; 118(2):243-51. PMC: 3138679. DOI: 10.1182/blood-2010-12-322909. View

Kamen B, Smith A . A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev. 2004; 56(8):1085-97. DOI: 10.1016/j.addr.2004.01.002. View

10.

Zhao R, Gao F, Goldman I . Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol. 2001; 61(7):857-65. DOI: 10.1016/s0006-2952(01)00532-9. View

11.

Hryniuk W, Bertino J . Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest. 1969; 48(11):2140-55. PMC: 297468. DOI: 10.1172/JCI106181. View

12.

Shane B . Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam Horm. 1989; 45:263-335. DOI: 10.1016/s0083-6729(08)60397-0. View

13.

Fisher R, Siegel B, Edell S, Oyesiku N, Morgenstern D, Messmann R . Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med. 2008; 49(6):899-906. DOI: 10.2967/jnumed.107.049478. View

14.

Raghunand N, Altbach M, van Sluis R, Baggett B, Taylor C, Bhujwalla Z . Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol. 1999; 57(3):309-12. DOI: 10.1016/s0006-2952(98)00306-2. View

15.

Andreassi 2nd J, Moran R . Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry. 2002; 41(1):226-35. DOI: 10.1021/bi015644d. View

16.

Kempin S, Gutierrez J, Wilson E, Lowery C, Diasio R . Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil. Cancer Invest. 2002; 20(7-8):992-5. DOI: 10.1081/cnv-120005915. View

17.

Chamberlain M . Leptomeningeal metastasis. Semin Neurol. 2010; 30(3):236-44. DOI: 10.1055/s-0030-1255220. View

18.

Taylor E, Kuhnt D, Shih C, Rinzel S, GRINDEY G, Barredo J . A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem. 1992; 35(23):4450-4. DOI: 10.1021/jm00101a023. View

19.

Gennari A, Sormani M, Pronzato P, Puntoni M, Colozza M, Pfeffer U . HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2007; 100(1):14-20. DOI: 10.1093/jnci/djm252. View

20.

Desmoulin S, Wang Y, Wu J, Stout M, Hou Z, Fulterer A . Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol. 2010; 78(4):577-87. PMC: 2981399. DOI: 10.1124/mol.110.065896. View